vs
AdvanSix Inc.（ASIX）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是AdvanSix Inc.的1.0倍（$373.9M vs $359.9M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs -0.8%，领先8.1%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 9.4%），AdvanSix Inc.自由现金流更多（$36.1M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
ASIX vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.0倍
$359.9M
营收增速更快
PAHC
高出11.5%
9.4%
净利率更高
PAHC
高出8.1%
-0.8%
自由现金流更多
ASIX
多$27.9M
$8.3M
两年增速更快
PAHC
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $373.9M |
| 净利润 | $-2.8M | $27.5M |
| 毛利率 | 7.6% | 35.5% |
| 营业利润率 | -0.7% | 13.5% |
| 净利率 | -0.8% | 7.3% |
| 营收同比 | 9.4% | 20.9% |
| 净利润同比 | -892.9% | 762.1% |
| 每股收益（稀释后） | $-0.11 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXPAHC
| Q4 25 | $359.9M | $373.9M | ||
| Q3 25 | $374.5M | $363.9M | ||
| Q2 25 | $410.0M | $378.7M | ||
| Q1 25 | $377.8M | $347.8M | ||
| Q4 24 | $329.1M | $309.3M | ||
| Q3 24 | $398.2M | $260.4M | ||
| Q2 24 | $453.5M | $273.2M | ||
| Q1 24 | $336.8M | $263.2M |
净利润ASIXPAHC
| Q4 25 | $-2.8M | $27.5M | ||
| Q3 25 | $-2.6M | $26.5M | ||
| Q2 25 | $31.4M | $17.2M | ||
| Q1 25 | $23.3M | $20.9M | ||
| Q4 24 | $352.0K | $3.2M | ||
| Q3 24 | $22.3M | $7.0M | ||
| Q2 24 | $38.9M | $752.0K | ||
| Q1 24 | $-17.4M | $8.4M |
毛利率ASIXPAHC
| Q4 25 | 7.6% | 35.5% | ||
| Q3 25 | 6.8% | 32.9% | ||
| Q2 25 | 14.3% | 29.0% | ||
| Q1 25 | 14.2% | 30.1% | ||
| Q4 24 | 3.4% | 32.9% | ||
| Q3 24 | 14.4% | 32.1% | ||
| Q2 24 | 17.9% | 31.9% | ||
| Q1 24 | 0.9% | 30.2% |
营业利润率ASIXPAHC
| Q4 25 | -0.7% | 13.5% | ||
| Q3 25 | -0.9% | 14.1% | ||
| Q2 25 | 7.7% | 8.9% | ||
| Q1 25 | 7.7% | 9.6% | ||
| Q4 24 | -3.9% | 8.3% | ||
| Q3 24 | 7.5% | 6.8% | ||
| Q2 24 | 11.5% | 6.7% | ||
| Q1 24 | -7.0% | 7.6% |
净利率ASIXPAHC
| Q4 25 | -0.8% | 7.3% | ||
| Q3 25 | -0.7% | 7.3% | ||
| Q2 25 | 7.7% | 4.5% | ||
| Q1 25 | 6.2% | 6.0% | ||
| Q4 24 | 0.1% | 1.0% | ||
| Q3 24 | 5.6% | 2.7% | ||
| Q2 24 | 8.6% | 0.3% | ||
| Q1 24 | -5.2% | 3.2% |
每股收益（稀释后）ASIXPAHC
| Q4 25 | $-0.11 | $0.67 | ||
| Q3 25 | $-0.10 | $0.65 | ||
| Q2 25 | $1.15 | $0.43 | ||
| Q1 25 | $0.86 | $0.51 | ||
| Q4 24 | $0.02 | $0.08 | ||
| Q3 24 | $0.82 | $0.17 | ||
| Q2 24 | $1.43 | $0.02 | ||
| Q1 24 | $-0.65 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $74.5M |
| 总债务越低越好 | — | $624.2M |
| 股东权益账面价值 | $815.2M | $332.4M |
| 总资产 | $1.7B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资ASIXPAHC
| Q4 25 | $19.8M | $74.5M | ||
| Q3 25 | $23.7M | $85.3M | ||
| Q2 25 | $18.4M | $77.0M | ||
| Q1 25 | $8.3M | $70.4M | ||
| Q4 24 | $19.6M | $67.1M | ||
| Q3 24 | $17.3M | $89.8M | ||
| Q2 24 | $12.1M | $114.6M | ||
| Q1 24 | $20.6M | $98.7M |
总债务ASIXPAHC
| Q4 25 | — | $624.2M | ||
| Q3 25 | — | $628.0M | ||
| Q2 25 | — | $631.7M | ||
| Q1 25 | — | $635.4M | ||
| Q4 24 | — | $639.1M | ||
| Q3 24 | — | $295.2M | ||
| Q2 24 | — | $312.1M | ||
| Q1 24 | — | — |
股东权益ASIXPAHC
| Q4 25 | $815.2M | $332.4M | ||
| Q3 25 | $818.2M | $311.7M | ||
| Q2 25 | $823.7M | $285.7M | ||
| Q1 25 | $794.4M | $266.0M | ||
| Q4 24 | $774.6M | $246.8M | ||
| Q3 24 | $766.4M | $258.5M | ||
| Q2 24 | $746.6M | $256.6M | ||
| Q1 24 | $713.2M | $270.1M |
总资产ASIXPAHC
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.5B | $966.3M | ||
| Q2 24 | $1.5B | $982.2M | ||
| Q1 24 | $1.5B | $979.0M |
负债/权益比ASIXPAHC
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 2.01× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 2.39× | ||
| Q4 24 | — | 2.59× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.22× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $8.3M |
| 自由现金流率自由现金流/营收 | 10.0% | 2.2% |
| 资本支出强度资本支出/营收 | 7.7% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 0.70× |
| 过去12个月自由现金流最近4个季度 | $6.4M | $47.3M |
8季度趋势，按日历期对齐
经营现金流ASIXPAHC
| Q4 25 | $63.7M | $19.4M | ||
| Q3 25 | $26.6M | $9.3M | ||
| Q2 25 | $21.1M | $21.3M | ||
| Q1 25 | $11.4M | $43.2M | ||
| Q4 24 | $64.2M | $3.1M | ||
| Q3 24 | $57.3M | $12.6M | ||
| Q2 24 | $50.2M | $28.4M | ||
| Q1 24 | $-36.2M | $11.4M |
自由现金流ASIXPAHC
| Q4 25 | $36.1M | $8.3M | ||
| Q3 25 | $66.0K | $-4.5M | ||
| Q2 25 | $-7.2M | $8.1M | ||
| Q1 25 | $-22.6M | $35.4M | ||
| Q4 24 | $29.8M | $-4.7M | ||
| Q3 24 | $26.8M | $3.0M | ||
| Q2 24 | $16.7M | $15.4M | ||
| Q1 24 | $-71.6M | $1.7M |
自由现金流率ASIXPAHC
| Q4 25 | 10.0% | 2.2% | ||
| Q3 25 | 0.0% | -1.2% | ||
| Q2 25 | -1.7% | 2.1% | ||
| Q1 25 | -6.0% | 10.2% | ||
| Q4 24 | 9.1% | -1.5% | ||
| Q3 24 | 6.7% | 1.2% | ||
| Q2 24 | 3.7% | 5.6% | ||
| Q1 24 | -21.3% | 0.6% |
资本支出强度ASIXPAHC
| Q4 25 | 7.7% | 3.0% | ||
| Q3 25 | 7.1% | 3.8% | ||
| Q2 25 | 6.9% | 3.5% | ||
| Q1 25 | 9.0% | 2.2% | ||
| Q4 24 | 10.4% | 2.5% | ||
| Q3 24 | 7.7% | 3.7% | ||
| Q2 24 | 7.4% | 4.8% | ||
| Q1 24 | 10.5% | 3.7% |
现金转化率ASIXPAHC
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | 0.67× | 1.24× | ||
| Q1 25 | 0.49× | 2.07× | ||
| Q4 24 | 182.29× | 0.97× | ||
| Q3 24 | 2.57× | 1.81× | ||
| Q2 24 | 1.29× | 37.80× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
